• Exploring the assessment of ADC efficacy through single-mouse in vitro PDXO, MiniPDX, PDX, and clinical MiniPDX models
• Demonstrating how models bridge preclinical findings to clinical indications, offering insights into drug efficacy and resistance
• Highlighting the integration of diverse models to accelerate ADC development and guide decision-making in pharmaceutical R&D
• Exploring opportunities for AI-enabled ADC development through the generation of integrated efficacy, pathology, and multi-omics datasets

Session Reserved for Lide